We are live on ! Find out more
PRVB

Provention Bio, Inc. Common Stock
PRVB

Delisted

PRVB was delisted on the 26th of April, 2023.

Back to rankings

125 hedge funds and large institutions have $197M invested in Provention Bio, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 48 increasing their positions, 32 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 32

28% more call options, than puts

Call options by funds: $8.58M | Put options by funds: $6.67M

26% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 19

4% more funds holding

Funds holding: 120 → 125 (+5)

21% less capital invested

Capital invested by funds: $249M → $197M (-$52.3M)

Holders
125
Holders Change
+5
Holders Change %
+4.17%
% of All Funds
2.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
48
Reduced
32
Closed
19
Calls
$8.58M
Puts
$6.67M
Net Calls
+$1.9M
Net Calls Change
-$4.34M

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$23.4M
2
SC
Sessa Capital
New York
+$22.5M
3
State Street
State Street
Massachusetts
+$1.96M
4
Millennium Management
Millennium Management
New York
+$1.84M
5
PPA
Parametric Portfolio Associates
Washington
+$1.79M

Top Sellers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
-$22.8M
2
PA
Perceptive Advisors
New York
-$15.4M
3
Two Sigma Advisers
Two Sigma Advisers
New York
-$7.16M
4
Two Sigma Investments
Two Sigma Investments
New York
-$4.04M
5
6CM
683 Capital Management
New York
-$2.68M

PRVB Hedge Fund Activity: Q2 2021 in Review

125 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q2 2021, worth a combined $197M — down 21% from $249M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new PRVB positions and 19 closed out — a net gain of 5 holders — while 48 added to existing stakes and 32 trimmed.

The largest buyer was VR Adviser, opening a new position worth an estimated $23.4M. The largest seller was Gilder Gagnon Howe & Co, cutting an estimated $22.8M.

  • 125 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q2 2021, up from 120 in Q1 2021.
  • Funds reported $197M of Provention Bio, Inc. Common Stock stock for Q2 2021, down 21% quarter-over-quarter.
  • 24 funds opened new Provention Bio, Inc. Common Stock positions in Q2 2021 and 19 closed out, a net change of +5 holders.
  • The largest Provention Bio, Inc. Common Stock buyer in Q2 2021 was VR Adviser, an estimated $23.4M added.
  • The largest Provention Bio, Inc. Common Stock seller in Q2 2021 was Gilder Gagnon Howe & Co, an estimated $22.8M sold.

Based on aggregated 13F filings for Q2 2021.